Literature DB >> 28432083

Optimal CD4 T cell priming after LPS-based adjuvanticity with CD134 costimulation relies on CXCL9 production.

Paurvi Shinde1, Wenhai Liu1, Antoine Ménoret1,2, Andrew D Luster3, Anthony T Vella4.   

Abstract

LPS is a powerful adjuvant, and although LPS-mediated TLR4 signaling has been exquisitely delineated, the in vivo mechanism of how TLR4 responses impact T cell priming is far less clear. Besides costimulation, TNF and type 1 IFN are dominant cytokines released after TLR4 activation and can shape T cell responses, but other downstream factors have not been examined extensively. Depending on context, we show that IFNαR1 blockade resulted in minor to major effects on specific CD4 T cell clonal expansion. To help explain these differences, it was hypothesized that IFNαR1 blockade would inhibit specific T cell migration by reducing chemokine receptor signaling, but specific CD4 T cells from IFNαR1-blocked mice were readily able to migrate in response to specific chemokines. Next, we examined downstream factors and found that type 1 IFN signaling was necessary for chemokine production, even when mice were immunized with specific Ag with LPS and CD134 costimulation. IFNαR1 signaling promoted CXCL9 and CXCL10 synthesis, suggesting that these chemokines might be involved in the LPS and CD134 costimulation response. After immunization, we show that CXCL9 blockade inhibited CD4 T cell accumulation in the liver but also in LNs, even in the presence of elevated serum IFN-β levels. Thus, whereas type 1 IFN might have direct effects on primed CD4 T cells, the downstream chemokines that play a role during migration also impact accumulation. In sum, CXCL9 production is a key benchmark for productive CD4 T cell vaccination strategies. © Society for Leukocyte Biology.

Entities:  

Keywords:  T cell expansion; TLR4; Type I IFN

Mesh:

Substances:

Year:  2017        PMID: 28432083      PMCID: PMC5470836          DOI: 10.1189/jlb.1A0616-261RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  86 in total

1.  Immunological adjuvants promote activated T cell survival via induction of Bcl-3.

Authors:  T C Mitchell; D Hildeman; R M Kedl; T K Teague; B C Schaefer; J White; Y Zhu; J Kappler; P Marrack
Journal:  Nat Immunol       Date:  2001-05       Impact factor: 25.606

2.  IL-18 bridges innate and adaptive immunity through IFN-gamma and the CD134 pathway.

Authors:  Joseph R Maxwell; Rajwardhan Yadav; Robert J Rossi; Carl E Ruby; Andrew D Weinberg; Hector L Aguila; Anthony T Vella
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

3.  Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses.

Authors:  I Gramaglia; A D Weinberg; M Lemon; M Croft
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

4.  Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins.

Authors:  A D Luster; J C Unkeless; J V Ravetch
Journal:  Nature       Date:  1985 Jun 20-26       Impact factor: 49.962

Review 5.  Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance.

Authors:  Melissa Swiecki; Marco Colonna
Journal:  Immunol Rev       Date:  2010-03       Impact factor: 12.988

Review 6.  Evolving synergistic combinations of targeted immunotherapies to combat cancer.

Authors:  Ignacio Melero; David M Berman; M Angela Aznar; Alan J Korman; José Luis Pérez Gracia; John Haanen
Journal:  Nat Rev Cancer       Date:  2015-08       Impact factor: 60.716

7.  CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro.

Authors:  Simon Rothenfusser; Veit Hornung; Maha Ayyoub; Stefanie Britsch; Andreas Towarowski; Anne Krug; Anja Sarris; Norbert Lubenow; Daniel Speiser; Stefan Endres; Gunther Hartmann
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

Review 8.  Accelerating next-generation vaccine development for global disease prevention.

Authors:  Wayne C Koff; Dennis R Burton; Philip R Johnson; Bruce D Walker; Charles R King; Gary J Nabel; Rafi Ahmed; Maharaj K Bhan; Stanley A Plotkin
Journal:  Science       Date:  2013-05-31       Impact factor: 47.728

9.  Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α.

Authors:  Eyad Elkord; Deborah J Burt; Anette Sundstedt; Örjan Nordle; Gunnar Hedlund; Robert E Hawkins
Journal:  Oncotarget       Date:  2015-02-28

10.  TRIF is required for TLR4 mediated adjuvant effects on T cell clonal expansion.

Authors:  Siva K Gandhapudi; Paula M Chilton; Thomas C Mitchell
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

View more
  2 in total

1.  The Protective Role of IL-36/IL-36R Signal in Con A-Induced Acute Hepatitis.

Authors:  Xiaofang Wang; Yuejin Liang; Hui Wang; Biao Zhang; Lynn Soong; Jiyang Cai; Panpan Yi; Xuegong Fan; Jiaren Sun
Journal:  J Immunol       Date:  2022-01-19       Impact factor: 5.422

2.  Unbiased analysis of peripheral blood mononuclear cells reveals CD4 T cell response to RSV matrix protein.

Authors:  Juilee Thakar; Yu Qian; Lauren Benoodt; David Roumanes; Xing Qiu; Nathan Laniewski; ChinYi Chu; Christopher Slaunwhite; Lu Wang; Aishwarya Mandava; Ivan Chang; Ann R Falsey; Mary T Caserta; Thomas J Mariani; Richard H Scheuermann; Edward E Walsh; David J Topham
Journal:  Vaccine X       Date:  2020-04-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.